Phosphoproteomic Analysis Reveals a Different Proteomic Profile in Pediatric Patients With T-Cell Lymphoblastic Lymphoma or T-Cell Acute Lymphoblastic Leukemia.
AKT/mTOR
JAK/STAT (janus kinase/signal transducer and activator of transcription)
T-ALL
T-LBL
phosphoproteomics analysis
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
05
04
2022
accepted:
13
06
2022
entrez:
25
7
2022
pubmed:
26
7
2022
medline:
26
7
2022
Statut:
epublish
Résumé
T-cell lymphoblastic lymphoma (T-LBL) and lymphoblastic leukemia (T-ALL) arise from the transformation of precursor T-cells sharing common morphological and immunophenotypic features. Despite this, T-LBL and T-ALL show different genomic/transcriptomic profiles and whether they represent two distinct disease entities or variant manifestations of the same disease is still a matter of debate. In this work, we performed a Reverse Phase Protein Array study on T-LBL and T-ALL samples and demonstrated that they are characterized by a different phosphoproteomic profile. Indeed, T-LBLs showed the hyperactivation of FAK/ERK1/2 and AKT/mTOR pathways, whereas JAK/STAT pathway was significantly hyperphosphorylated in T-ALLs. Moreover, since the only criteria for discriminating T-LBL from T-ALL is blasts' infiltration below 25% in the bone marrow and lymphoma patients can present with a percentage of blasts close to this cut-off, a biomarker that could help distinguishing the two diseases would be of great help for the clinical diagnosis and treatment decision. Pursuing this aim, we identified a proteomic signature of six proteins whose expression/activation was able to discriminate stage IV T-LBL from T-ALL. Moreover, we demonstrated that AKT hyperphosphorylation alone was able to distinguish stage IV T-LBL from both T-ALL and stage III T-LBL. Concluding, these data demonstrate that T-ALL and T-LBL bear different phosphoproteomic profiles, further sustaining the hypothesis of the two disease as different entities and paving the way for the identification of new biomarkers able to distinguish stage IV T-LBL from T-ALL disease, so far based only on BM involvement criteria.
Identifiants
pubmed: 35875136
doi: 10.3389/fonc.2022.913487
pmc: PMC9304622
doi:
Types de publication
Journal Article
Langues
eng
Pagination
913487Informations de copyright
Copyright © 2022 Veltri, Lovisa, Cortese, Pillon, Carraro, Cesaro, Provenzi, Buffardi, Francescato, Biffi, Buldini, Conter, Serafin and Mussolin.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The reviewer LM declared a shared affiliation with the author VC to the handling editor at the time of review.
Références
Semin Oncol. 1980 Sep;7(3):332-9
pubmed: 7414342
Diagnostics (Basel). 2021 Sep 01;11(9):
pubmed: 34573936
Leukemia. 2016 Jan;30(1):94-103
pubmed: 26216197
Cancer Cell. 2010 Oct 19;18(4):353-66
pubmed: 20951945
Haematologica. 2017 Dec;102(12):2086-2096
pubmed: 28983060
Br J Haematol. 2005 Oct;131(1):39-49
pubmed: 16173961
Pediatr Blood Cancer. 2015 Aug;62(8):1388-94
pubmed: 25755200
Blood. 2011 Aug 25;118(8):2077-84
pubmed: 21719599
Sci Rep. 2021 Jan 12;11(1):769
pubmed: 33436855
J Immunol. 2007 Mar 1;178(5):2623-9
pubmed: 17312100
Nat Rev Cancer. 2014 Sep;14(9):598-610
pubmed: 25098269
Leukemia. 2010 Feb;24(2):255-64
pubmed: 20016536
Blood Adv. 2020 Jul 28;4(14):3466-3473
pubmed: 32722786
Cancer Cell. 2010 Oct 19;18(4):297-9
pubmed: 20951938
Nature. 2012 Jan 11;481(7380):157-63
pubmed: 22237106
Leukemia. 2016 Apr;30(4):970-3
pubmed: 26216196
Biochem Pharmacol. 2018 Sep;155:213-223
pubmed: 30006194
Blood. 1994 Sep 1;84(5):1361-92
pubmed: 8068936
Cancers (Basel). 2021 Jul 24;13(15):
pubmed: 34359628
Genes Chromosomes Cancer. 2011 Dec;50(12):1063-75
pubmed: 21987448
Cytometry B Clin Cytom. 2018 Jan;94(1):82-93
pubmed: 28187514
Lancet Haematol. 2016 Feb;3(2):e80-6
pubmed: 26853647
Blood. 2016 May 19;127(20):2391-405
pubmed: 27069254
Exp Ther Med. 2020 Mar;19(3):1997-2007
pubmed: 32104259
PLoS Med. 2016 Dec 20;13(12):e1002200
pubmed: 27997540
Am J Clin Pathol. 2015 Sep;144(3):411-22
pubmed: 26276771
J Exp Clin Cancer Res. 2019 Jun 11;38(1):250
pubmed: 31186061
Oncogene. 2013 May 23;32(21):2601-13
pubmed: 22869151
Blood Cancer J. 2020 Apr 28;10(4):45
pubmed: 32345961
Breast Cancer Res. 2015 Mar 28;17:47
pubmed: 25880415
Br J Haematol. 2015 Jan;168(2):308-13
pubmed: 25160903